Tofersen, an antisense oligonucleotide designed to reduce synthesis of SOD1 protein via ribonuclease H-dependent degradation of SOD1 mRNA [16, 20, 21], is an investigational drug under development for the treatment of SOD1-ALS. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.